Clinical Trials · NCT06948422
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
- Phase
- Phase 3
- Recruitment status
- Active Not Recruiting
- Sponsor
- Eli Lilly and Company
- Enrollment
- 974
- Start date
- Apr 2025
- Locations
- 100 sites, 11 countries
- Primary endpoint
- Number of Participants Allocated to Each ISA